We have eagerly awaited seeing the actual results since the sponsor company (Novo Nordisk) issued a press release in August that proclaimed a 20% relative reduction of cardiovascular death, heart attack or stroke, the primary endpoint of the trial
The brand is committed to open education around semaglutide and sustainable weight management, helping patients make informed choices
typically resolves within hours [4] [6]
Here are things worth noting to share with your provider: Your current weight, along with any recent patterns youve noticed
Since these drugs are both tirzepatide injections sold under different names, some people may wonder whether its possible to switch from Zepbound to Mounjaro for better insurance coverage or other reasons
An increase in the incidence of cardiac arrhythmias, mainly supraventricular, was noted in some trial arms